.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cerilliant
Harvard Business School
Covington
QuintilesIMS
McKinsey
US Army
Federal Trade Commission
McKesson
Cipla

Generated: December 15, 2017

DrugPatentWatch Database Preview

RESCULA Drug Profile

« Back to Dashboard

Which patents cover Rescula, and what generic alternatives are available?

Rescula is a drug marketed by Sucampo Pharma Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-one patent family members in eighteen countries and one supplementary protection certificate in one country.

The generic ingredient in RESCULA is unoprostone isopropyl. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the unoprostone isopropyl profile page.

Summary for RESCULA

Drug patent expirations by year for RESCULA

Pharmacology for RESCULA

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RESCULA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
Sucampo Pharma LlcRESCULAunoprostone isopropylSOLUTION/DROPS;OPHTHALMIC021214-001Aug 3, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for RESCULA

Drugname Dosage Strength RLD Submissiondate
unoprostone isopropylOphthalmic Solution0.15%Rescula5/12/2014

International Patent Family for Tradename: RESCULA

Country Document Number Estimated Expiration
South Korea20080012407► Subscribe
Czech Republic20023092► Subscribe
MexicoPA02008967► Subscribe
South Africa200207140► Subscribe
Australia2001241143► Subscribe
World Intellectual Property Organization (WIPO)0168072► Subscribe
New Zealand521325► Subscribe
South Korea20020081438► Subscribe
Brazil0109192► Subscribe
Norway20024381► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RESCULA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00135Netherlands► SubscribePRODUCT NAME: UNOPROSTONEZUUR, DESGEWENST IN DE VORM VAN EEN ESTER OF EEN ZOUT; NATL REGISTRATION NO/DATE: RVG 28628 20030708; FIRST REGISTRATION: FR 359 911-5 AND 359 912-1 20020917
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Deloitte
Citi
Farmers Insurance
Novartis
McKesson
Fuji
AstraZeneca
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot